Cocoa flavanol metabolites activate HNF-3β, Sp1, and NFY-mediated transcription of apolipoprotein AI in human cells

Molecular Nutrition and Food Research

Volumn 57, Issue 6, 2013, Pages 986-995

  Oleaga, Carlota ^a   Ciudad, Carlos J ^a   Izquierdo Pulido, Maria ^a   Noé, Véronique ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ApoAI; Cocoa metabolites; Nutrigenomics; Polyphenols; SITE B

Indexed keywords

3' O METHYLEPICATECHIN; 3'-O-METHYLEPICATECHIN; APOLIPOPROTEIN A1; ATORVASTATIN; CATECHIN; CCAAT BINDING FACTOR; DRUG DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; FLAVONOID; HEPATOCYTE NUCLEAR FACTOR 3BETA; HEPATOCYTE NUCLEAR FACTOR 4; HEPTANOIC ACID DERIVATIVE; HNF4A PROTEIN, HUMAN; NUCLEAR FACTOR Y; PYRROLE DERIVATIVE; TRANSCRIPTION FACTOR SP1;

ARTICLE; BINDING SITE; CACAO; CELL STRAIN HEPG2; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PROMOTER REGION; UPREGULATION;

APOLIPOPROTEIN A-I; BINDING SITES; CACAO; CATECHIN; CCAAT-BINDING FACTOR; ESTROGEN RECEPTOR ALPHA; FLAVONOIDS; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HEPATOCYTE NUCLEAR FACTOR 4; HEPTANOIC ACIDS; HUMANS; PROMOTER REGIONS, GENETIC; PYRROLES; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; UP-REGULATION;

THEOBROMA CACAO;

EID: 84878898795     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200507     Document Type: Article

References (67)

1. WHO, World Health Organization. Causes of death 2008 summary tables, 2011. http://apps.who.int/ghodata/?vid=10012
2. Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362, 801-809.
3. Dominiczak, M. H., Caslake, M. J., Apolipoproteins: metabolic role and clinical biochemistry applications. Ann. Clin. Biochem. 2011, 48, 498-515.
4. WHO, World Health Organization. Global Strategy on Diet, Physical Activity and Health. Cardiovascular disease: prevention and control, 2012. http://www.who.int/dietphysicalactivity/publications/
5. Weber, C., Noels, H., Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17, 1410-1422.
6. Duffy, D., Rader, D. J., Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006, 113, 1140-1150.
7. Tall, A. R., Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 1990, 86, 379-384.
8. Brown, W. M., Chiacchia, F. S., Therapies to increase ApoA-I and HDL-cholesterol levels. Drug Target Insights 2008, 3, 45-54.
9. Smith, J. D., Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 151-155.
10. Wong, N. C., Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 2007, 8, 718-728.
11. Lamon-Fava, S., Micherone, D., Regulation of apoA-I gene expression: mechanism of action of estrogen and genistein. J. Lipid Res. 2004, 45, 106-112.
12. Sanders, T. A., Dean, T. S., Grainger, D., Miller, G. J. et al., Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. Am. J. Clin. Nutr. 2002, 76, 373-377.
13. Yasuda, A., Natsume, M., Osakabe, N., Kawahata, K. et al., Cacao polyphenols influence the regulation of apolipoprotein in HepG2 and Caco2 cells. J. Agric. Food Chem. 2011, 59, 1470-1476.
14. Flammer, A. J., Sudano, I., Wolfrum, M., Thomas, R. et al., Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. Eur. Heart J. 2012, 33, 2172-2180.
15. Hooper, L., Kay, C., Abdelhamid, A., Kroon, P. A. et al., Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am. J. Clin. Nutr. 2012, 95, 740-751.
16. Corti, R., Flammer, A. J., Hollenberg, N. K., Luscher, T. F., Cocoa and cardiovascular health. Circulation 2009, 119, 1433-1441.
17. Heneman, K., Zidenberg-Cherr, S., Some Facts About Catechins. University of California Davis, CA 2008, pp. 1-5.
18. Katz, D. L., Doughty, K., Ali, A., Cocoa and chocolate in human health and disease. Antioxid. Redox Signal 2011, 15, 2779-2811.
19. Heiss, C., Schroeter, H., Balzer, J., Kleinbongard, P. et al., Endothelial function, nitric oxide, and cocoa flavanols. J. Cardiovasc. Pharmacol. 2006, 47, S128-S135.
20. Schewe, T., Steffen, Y., Sies, H., How do dietary flavanols improve vascular function? A position paper. Arch. Biochem. Biophys. 2008, 476, 102-106.
21. Actis-Goretta, L., Leveques, A., Giuffrida, F., Romanov-Michailidis, F. et al., Elucidation of (-)-epicatechin metabolites after ingestion of chocolate by healthy humans. Free Radic. Biol. Med. 2012, 53, 787-795.
22. Rimbach, G., Melchin, M., Moehring, J., Wagner, A. E., Polyphenols from cocoa and vascular health-a critical review. Int. J. Mol. Sci. 2009, 10, 4290-4309.
23. Rodriguez-Mateos, A., Jose Oruna-Concha, M., Kwik-Uribe, C., Vidal, A. et al., Influence of sugar type on the bioavailability of cocoa flavanols. Br. J. Nutr. 2012, DOI: 10.1017/S0007114512000475.
24. Schroeter, H., Heiss, C., Balzer, J., Kleinbongard, P. et al., (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc. Natl. Acad. Sci. USA 2006, 103, 1024-1029.
25. Urpi-Sarda, M., Monagas, M., Khan, N., Llorach, R. et al., Targeted metabolic profiling of phenolics in urine and plasma after regular consumption of cocoa by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A. 2009, 1216, 7258-7267.
26. Roura, E., Andres-Lacueva, C., Jauregui, O., Badia, E. et al., Rapid liquid chromatography tandem mass spectrometry assay to quantify plasma (-)-epicatechin metabolites after ingestion of a standard portion of cocoa beverage in humans. J. Agric. Food Chem. 2005, 53, 6190-6194.
27. Cooper, K. A., Donovan, J. L., Waterhouse, A. L., Williamson, G., Cocoa and health: a decade of research. Br. J. Nutr. 2008, 99, 1-11.
28. Duenas, M., Gonzalez-Manzano, S., Surco-Laos, F., Gonzalez-Paramas, A. et al., Characterization of sulfated quercetin and epicatechin metabolites. J. Agric. Food Chem. 2012, 60, 3592-3598.
29. Chen, D., Wang, C. Y., Lambert, J. D., Ai, N. et al., Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem. Pharmacol. 2005, 69, 1523-1531.
30. Cren-Olive, C., Teissier, E., Duriez, P., Rolando, C., Effect of catechin O-methylated metabolites and analogues on human LDL oxidation. Free Radic. Biol. Med. 2003, 34, 850-855.
31. Lambert, J. D., Sang, S., Yang, C. S., Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol. Pharm. 2007, 4, 819-825.
32. Natsume, M., Osakabe, N., Yasuda, A., Osawa, T. et al., Inhibitory effects of conjugated epicatechin metabolites on peroxynitrite-mediated nitrotyrosine formation. J. Clin. Biochem. Nutr. 2008, 42, 50-53.
33. Spencer, J. P., Schroeter, H., Rechner, A. R., Rice-Evans, C., Bioavailability of flavan-3-ols and procyanidins: gastrointestinal tract influences and their relevance to bioactive forms in vivo. Antioxid. Redox Signal 2001, 3, 1023-1039.
34. Steffen, Y., Gruber, C., Schewe, T., Sies, H., Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch. Biochem. Biophys. 2008, 469, 209-219.
35. Zhu, Q. Y., Schramm, D. D., Gross, H. B., Holt, R. R. et al., Influence of cocoa flavanols and procyanidins on free radical-induced human erythrocyte hemolysis. Clin. Dev. Immunol. 2005, 12, 27-34.
36. Scalbert, A., Manach, C., Morand, C., Remesy, C. et al., Dietary polyphenols and the prevention of diseases. Crit. Rev. Food Sci. Nutr. 2005, 45, 287-306.
37. Granado-Serrano, A. B., Angeles Martin, M., Goya, L., Bravo, L. et al., Time-course regulation of survival pathways by epicatechin on HepG2 cells. J. Nutr. Biochem. 2009, 20, 115-124.
38. Argmann, C. A., Edwards, J. Y., Sawyez, C. G., O'Neil, C. H. et al., Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J. Biol. Chem. 2005, 280, 22212-22221.
39. Kawamoto, T., Kakizaki, S., Yoshinari, K., Negishi, M., Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. Mol. Endocrinol. 2000, 14, 1897-1905.
40. Lamon-Fava, S., Ordovas, J. M., Schaefer, E. J., Estrogen increases apolipoprotein (apo) A-I secretion in hep G2 cells by modulating transcription of the apo A-I gene promoter. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 2960-2965.
41. Zhang, X., Jiao, J. J., Bhavnani, B. R., Tam, S. P., Regulation of human apolipoprotein A-I gene expression by equine estrogens. J. Lipid Res. 2001, 42, 1789-1800.
42. Mencia, N., Selga, E., Rico, I., de Almagro, M. C. et al., Overexpression of S100A4 in human cancer cell lines resistant to methotrexate. BMC Cancer 2010, 10, 250.
43. Noe, V., Alemany, C., Chasin, L. A., Ciudad, C. J., Retinoblastoma protein associates with SP1 and activates the hamster dihydrofolate reductase promoter. Oncogene 1998, 16, 1931-1938.
44. Malik, S., Transcriptional regulation of the apolipoprotein AI gene. Front Biosci. 2003, 8, d360-d368.
45. Noe, V., Chen, C., Alemany, C., Nicolas, M. et al., Cell-growth regulation of the hamster dihydrofolate reductase gene promoter by transcription factor Sp1. Eur. J. Biochem. 1997, 249, 13-20.
46. Noe, V., Alemany, C., Nicolas, M., Ciudad, C. J., Sp1 involvement in the 4beta-phorbol 12-myristate 13-acetate (TPA) mediated increase in resistance to methotrexate in Chinese hamster ovary cells. Eur. J. Biochem. 2001, 268, 3163-3173.
47. Hargrove, G. M., Junco, A., Wong, N. C., Hormonal regulation of apolipoprotein AI. J. Mol. Endocrinol. 1999, 22, 103-111.
48. Harnish, D. C., Malik, S., Kilbourne, E., Costa, R. et al., Control of apolipoprotein AI gene expression through synergistic interactions between hepatocyte nuclear factors 3 and 4. J. Biol. Chem. 1996, 271, 13621-13628.
49. Ladias, J. A., Karathanasis, S. K., Regulation of the apolipoprotein AI gene by ARP-1, a novel member of the steroid receptor superfamily. Science 1991, 251, 561-565.
50. Rottman, J. N., Widom, R. L., Nadal-Ginard, B., Mahdavi, V. et al., A retinoic acid-responsive element in the apolipoprotein AI gene distinguishes between two different retinoic acid response pathways. Mol. Cell Biol. 1991, 11, 3814-3820.
51. Mantovani, R., Pessara, U., Tronche, F., Li, X. Y. et al., Monoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription. EMBO J. 1992, 11, 3315-3322.
52. Pascal, E., Tjian, R., Different activation domains of Sp1 govern formation of multimers and mediate transcriptional synergism. Genes Dev. 1991, 5, 1646-1656.
53. Green, S., Walter, P., Kumar, V., Krust, A. et al., Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320, 134-139.
54. Maejima, T., Yamazaki, H., Aoki, T., Tamaki, T. et al., Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem. Biophys. Res. Commun. 2004, 324, 835-839.
55. Martin, G., Duez, H., Blanquart, C., Berezowski, V. et al., Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 2001, 107, 1423-1432.
56. Cirillo, L. A., Lin, F. R., Cuesta, I., Friedman, D. et al., Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol. Cell 2002, 9, 279-289.
57. Taylor, A. H., Fox-Robichaud, A. E., Egan, C., Dionne, J. et al., Oestradiol decreases rat apolipoprotein AI transcription via promoter site B. J. Mol. Endocrinol. 2000, 25, 207-219.
58. Freitas, H. S., Schaan, B. D., David-Silva, A., Sabino-Silva, R. et al., SLC2A2 gene expression in kidney of diabetic rats is regulated by HNF-1alpha and HNF-3beta. Mol. Cell Endocrinol. 2009, 305, 63-70.
59. Vecchini, A., Ceccarelli, V., Nocentini, G., Riccardi, C. et al., Dietary PUFA modulate the expression of proliferation and differentiation markers in Morris 3924A hepatoma cells. Biochim. Biophys. Acta 2005, 1737, 138-144.
60. Kuang, Y. L., Paulson, K. E., Lichtenstein, A. H., Matthan, N. R. et al., Docosahexaenoic acid suppresses apolipoprotein A-I gene expression through hepatocyte nuclear factor-3beta. Am. J. Clin. Nutr. 2011, 94, 594-600.
61. Papazafiri, P., Ogami, K., Ramji, D. P., Nicosia, A. et al., Promoter elements and factors involved in hepatic transcription of the human ApoA-I gene positive and negative regulators bind to overlapping sites. J. Biol. Chem. 1991, 266, 5790-5797.
62. Novak, E. M., Bydlowski, S. P., NFY transcription factor binds to regulatory element AIC and transactivates the human apolipoprotein A-I promoter in HEPG2 cells. Biochem. Biophys. Res. Commun. 1997, 231, 140-143.
63. Haas, M. J., Horani, M. H., Wong, N. C., Mooradian, A. D., Induction of the apolipoprotein AI promoter by Sp1 is repressed by saturated fatty acids. Metabolism 2004, 53, 1342-1348.
64. Lam, J. K., Matsubara, S., Mihara, K., Zheng, X. L. et al., Insulin induction of apolipoprotein AI, role of Sp1. Biochemistry 2003, 42, 2680-2690.
65. Zheng, X. L., Matsubara, S., Diao, C., Hollenberg, M. D. et al., Activation of apolipoprotein AI gene expression by protein kinase A and kinase C through transcription factor, Sp1. J. Biol. Chem. 2000, 275, 31747-31754.
66. Goto, T., Saito, Y., Morikawa, K., Kanamaru, Y. et al., Epigallocatechin gallate changes mRNA expression level of genes involved in cholesterol metabolism in hepatocytes. Br. J. Nutr. 2012, 107, 769-773.
67. Lee, M. S., Park, J. Y., Freake, H., Kwun, I. S. et al., Green tea catechin enhances cholesterol 7alpha-hydroxylase gene expression in HepG2 cells. Br. J. Nutr. 2008, 99, 1182-1185.